Winter Rheumatology Symposium

ACR Disclosure Statement
The ACR is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern. Educational activities provided by the ACR must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias.

Faculty participating in an ACR-sponsored activity must disclose to the planning committee and audience any financial or other relationship(s) including, but not limited to:

1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan
2. Research grants
3. Employment (full or part-time)
4. Ownership or partnership
5. Consulting fees or other remuneration (payment)
6. Non-remunerative positions of influence such as officer, board member, trustee, or public spokesperson
7. Receipt of royalties
8. Speakers' bureau
9. Other

The planning committee and faculty reported the following disclosures.

Planning Committee

• Joel Block, MD - Daiichi-Sankyo⁷, GlaxoSmithKline ⁵, Medivir Inc⁵, Novartis², Omeros Inc, Pfizer ²
• Maria Dall'Era, MD - Janssen⁵
• Michael Weinblatt, MD - AbbVie⁵, Amgen^{5, 2}, Arena⁵, Bristol-Myers Squibb^{5, 2}, Canfite^1,, Corrona⁵, Crescendo BioScience Inc.^{5, 2}, Eli Lilly^{5, 2}, Gilead Sciences^5,, Glaxo Smith Kline⁵, Hoffman La Roche-Genentech⁵, Horizon Pharmaceuticals⁵, Inmedix¹, Lycera¹, Novartis⁵, Pfizer⁵, Regeneron Pharmaceuticals², Samsung⁵, Sanofi², Scipher Medicine^{5, 1}, Set Point^,5, Vorso^1,5

Faculty

• Bonnie Bermas, MD - No financial relationships to disclose
• Jean Marie Connors, MD - No financial relationships to disclose
• Leslie Crofford, MD - No financial relationships to disclose
• Jeffrey R Curtis, MD, MS, MPH - AbbVie^{5, 2}, Amgen Inc^{5, 2}, BMS ^{5, 2}, Corrona^{5, 2}, Eli Lilly and Co. ^{5, 2}, Janssen^{5, 2}, Myriad ^{5, 2}, Pfizer Inc ^{5, 2}, Regeneron: 5, 2; Roche/Genentech^{5, 2}; UCB: 5, 2
• Michael Holers, MD - AbbVie, Amgen, BMS, Genzyme, Janssen, Novartis, Pfizer, Roche, Sandoz, UCB^{5, 5}, AbbVie, Celgene ⁵, AdMIRx, Inc. ^{5, 2, 6, 1, 7}, Alexion⁷, GSK⁵, Trios⁵
• J. Michelle Kahlenberg, MD, PhD - AstraZeneca⁵, Bristol-Myers Squibb⁵, Celgene^2,, Eli Lilly⁵
• Nancy Lane, MD - Amgen: ⁵, Pfizer⁵
• Peter McBride - No financial relationships to disclose
• Christopher Ritchlin, MD, MPH - AbbVie, Amgen, Abbvie, BMS, Janssen, Lilly, Novartis, Pfizer, UCB ^{5, 2}
• Robert Schoen, MD - No financial relationships to disclose
• Ulrich Specks, MD - AstraZeneca^5,, Bristol-Myers Squibb², ChemoCentryx², InflRx GmBH²